DRG Epidemiology’s coverage of epilepsy comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the prevalence of epilepsy for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets. In addition to forecasting prevalent patient populations, we estimate the number of drug-treatment opportunities in specific lines of therapyinthe major mature pharmaceutical markets.
DRG Epidemiology’s epilepsy forecast will answer the following questions:
- Of all people diagnosed with epilepsy, how many in each of the major mature pharmaceutical markets are drug-treated?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of epilepsy over the forecast period?
All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is provided for full transparency into research and methods.
In addition to the total number of cases for each forecast year, DRG Epidemiology provides at least ten years of forecast data for the following subpopulations:
- Diagnosed prevalent cases of epilepsy by seizure level.
- Diagnosed prevalent cases of epilepsy with status epilepticus.
- Diagnosed prevalent cases by drug-treatment status.
- Drug-treated prevalent cases by drug-resistance status.
- Diagnosed prevalent cases based on risk of acute repetitive seizure.
- Diagnosed prevalence of Lennox-Gastaut cases with intractable epilepsy.
- Diagnosed prevalent cases of Lennox-Gastaut syndrome with sudden tonic or atonic falls.
- Diagnosed prevalent cases of Lennox-Gastaut syndrome with status epilepticus.
- SCN1A mutation status in Dravet syndrome.
Note: Coverage may vary by country.
- Epilepsy - Epidemiology - Mature Markets
- Key Findings
- Diagnosed Prevalence of Epilepsy per 1,000 People of All Ages in 2021 and 2041
- Relative Sizes of the Contributing Factors to the Trend in Diagnosed Prevalent Cases of Epilepsy Over the Next 20 Years
- Analysis of Diagnosed Prevalent Cases of Epilepsy in 2021 by Type of Seizure
- Epidemiology Data
- Diagnosed Prevalent Cases of Epilepsy
- Type of Epileptic Seizure
- Epilepsy With Status Epilepticus
- Drug-Resistant Epilepsy
- Acute Repetitive Seizures
- Drug-Treated Prevalent Cases of Epilepsy
- Diagnosed Prevalent Cases of Lennox-Gastaut Syndrome
- Lennox-Gastaut Syndrome With Intractable Epilepsy
- Lennox-Gastaut Syndrome With Sudden Tonic or Atonic Falls
- Lennox-Gastaut Syndrome With Status Epilepticus
- Diagnosed Prevalent Cases of Dravet Syndrome
- Dravet Syndrome by Severity
- Dravet Syndrome With Status Epilepticus
- Dravet Syndrome With SCN1A Mutation
- Diagnosed Incident Cases of Dravet Syndrome
- Diagnosed Prevalent Cases of West Syndrome
- Diagnosed Prevalent Cases of Childhood Absence Epilepsy
- Reference Materials
- Literature Review
- Studies Included in the Analysis of Epilepsy
- Studies Excluded From the Analysis of Epilepsy
- Risk/Protective Factors
- Risk / Protective Factors for Epilepsy